ACM
EW icon

Azimuth Capital Management’s Edwards Lifesciences EW Stock Holding History

Azimuth Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$12M Buy
102,107
+1,347
+1% +$151K 0.51% 69
2021
Q4 		$13.1M Sell
100,760
-668
-0.7% -$77.9K 0.53% 69
2021
Q3 		$11.5M Sell
101,428
-193
-0.2% -$22K 0.49% 75
2021
Q2 		$10.5M Buy
101,621
+1,707
+2% +$161K 0.45% 80
2021
Q1 		$8.36M Sell
99,914
-39
-0% -$3.3K 0.4% 91
2020
Q4 		$9.12M Sell
99,953
-77,877
-44% -$6.46M 0.45% 82
2020
Q3 		$14.2M Buy
177,830
+23,126
+15% +$1.8M 0.84% 35
2020
Q2 		$10.7M Buy
154,704
+870
+0.6% +$61.8K 0.68% 53
2020
Q1 		$9.67M Buy
153,834
+12,030
+8% +$868K 0.73% 47
2019
Q4 		$11M Buy
141,804
+2,496
+2% +$195K 0.67% 53
2019
Q3 		$10.2M Sell
139,308
-30,216
-18% -$2.12M 0.67% 51
2019
Q2 		$10.4M Buy
169,524
+5,478
+3% +$331K 0.69% 49
2019
Q1 		$10.5M Sell
164,046
-34,146
-17% -$1.95M 0.7% 42
2018
Q4 		$10.1M Sell
198,192
-3,495
-2% -$177K 0.77% 41
2018
Q3 		$11.7M Buy
201,687
+5,916
+3% +$289K 0.78% 38
2018
Q2 		$9.5M Sell
195,771
-2,235
-1% -$104K 0.68% 50
2018
Q1 		$9.21M Sell
198,006
-4,995
-2% -$217K 0.68% 49
2017
Q4 		$7.63M Buy
203,001
+6,735
+3% +$247K 0.55% 68
2017
Q3 		$7.15M Sell
196,266
-23,004
-10% -$877K 0.54% 74
2017
Q2 		$8.64M Sell
219,270
-11,625
-5% -$424K 0.68% 48
2017
Q1 		$7.24M Sell
230,895
-1,080
-0.5% -$33.8K 0.58% 61
2016
Q4 		$7.25M Sell
231,975
-33,240
-13% -$1.08M 0.62% 58
2016
Q3 		$10.7M Buy
265,215
+5,322
+2% +$200K 0.93% 31
2016
Q2 		$8.64M Sell
259,893
-38,739
-13% -$1.33M 0.77% 42
2016
Q1 		$8.78M Buy
298,632
+42,840
+17% +$1.18M 0.84% 40
2015
Q4 		$6.73M Buy
255,792
+5,490
+2% +$143K 0.66% 53
2015
Q3 		$5.93M Buy
250,302
+6,810
+3% +$164K 0.62% 53
2015
Q2 		$5.78M Buy
243,492
+10,440
+4% +$236K 0.56% 58
2015
Q1 		$5.53M Buy
233,052
+9,612
+4% +$216K 0.54% 63
2014
Q4 		$4.74M Buy
+223,440
New +$4.49M 0.49% 69

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Azimuth Capital Management's EW Position: Q1 2022 in Review

Azimuth Capital Management increased its Edwards Lifesciences (EW) stake by 1.3% in Q1 2022, buying an estimated $151K and bringing the position to 102,107 shares worth $12M. The position accounts for 0.51% of the portfolio, ranked #69.

Azimuth Capital Management first reported a position in EW in Q4 2014 and has held it in 30 quarters since. The position peaked at $14.2M in Q3 2020. 1,314 funds tracked by Wall St. Rank hold EW as of Q1 2022.

  • Azimuth Capital Management held 102,107 shares of Edwards Lifesciences worth $12M as of Q1 2022.
  • Azimuth Capital Management bought 1,347 Edwards Lifesciences shares in Q1 2022, an estimated $151K.
  • Edwards Lifesciences made up 0.51% of Azimuth Capital Management's portfolio in Q1 2022, its #69 holding.
  • Azimuth Capital Management first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 30 quarters since.
  • Azimuth Capital Management's Edwards Lifesciences position peaked at $14.2M in Q3 2020.
  • 1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Azimuth Capital Management's 13F filing for Q1 2022, filed 13 May 2022.